SMIMA1091U Quality by Design (QbD) in Pharmaceutical Development
Master of Industrial Drug Development (MIND) - elective
The course is intended as continuing professional development (CPD)
for professionals in the pharmaceutical industry, particularly in
production, regulatory affairs and quality functions. The course
will be an excellent introduction for those less familiar with QbD
and will provide those with more experience on QbD with new ideas
on how to further implement the company’s QbD
programme.
Quality by Design (QbD) lies at the core of modern pharmaceutical development, offering a scientifically sound and cost-efficient pathway to delivering high-quality medicines to patients. Global regulatory authorities — including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) — now emphasize QbD principles as an integral part of regulatory submissions. As a result, QbD has become a cornerstone of streamlined, risk-based drug development and manufacturing.
This course provides an in-depth exploration of QbD principles, spanning quality risk management, formal experimental design, and process analytical technology (PAT). Guided by leading experts from industry, academia, and regulatory agencies, participants will gain both a conceptual understanding and practical insight into how QbD strategies can be effectively implemented within their organizations.
Through interactive lectures and practical demonstrations, the course equips participants with the skills to apply QbD methodologies across the product lifecycle — from design to commercialization.
Key Learning Topics:
Fundamentals of risk analysis and quality management
Developing the Quality Target Product Profile (QTPP)
Identifying Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs)
Applying Design of Experiments (DoE): from basic screening to advanced designs
Understanding Process Analytical Technologies (PAT): chemometrics, process monitoring, and measurement techniques
Navigating the risk-based regulatory framework for QbD implementation
Who Should Attend:
This course is designed for professionals and lifelong learners in
the pharmaceutical and biopharmaceutical sectors - including,
e.g., formulation scientists, process engineers, regulatory affairs
specialists, and quality professionals - who wish to enhance
their expertise in QbD principles and practical
applications.
After completing the course the student must have gained the
following knowledge, skills and competencies:
Knowledge
- summarize the principles of the QbD approach in pharmaceutical development and manufacturing
- demonstrate basic knowledge about risk management, design of experiments and PAT
- demonstrate basic knowledge about the relationship of the QbD approach into design space and further, into the regulatory framework
Skills
- apply basic risk analysis and design of experiments techniques into practical cases
identify and suggest suitable process analytical tools for a given manufacturing environment
Competencies
- work in a multidisciplinary risk management team
- plan and implement basic design of experiments (DoE) approach
suggest a QbD approach for constructing a design space.
The common course syllabus is a collection of legislation, presentations (hand-outs) and cases, approx. 300 pages.
• A bachelor's degree, a professional bachelor’s degree, a diploma degree, a master’s degree or equivalent within chemistry, biochemistry, pharmacy, medicine, biomedicine, human biology, molecular biology, veterinary sciences, health sciences, nursing, engineering or equivalent.
• At least two years of relevant work experience related to development of medicines
• Proficiency in English
- Category
- Hours
- Class Instruction
- 40
- Preparation
- 22,5
- Exam
- 20
- Total
- 82,5
- Credit
- 3 ECTS
- Type of assessment
- Written assignment
- Type of assessment details
- An essay based on a selected QbD case and the common course syllabus. The essay must be 8-15 pages.
- Aid
- All aids allowed
- Marking scale
- passed/not passed
- Censorship form
- No external censorship
- Exam period
Deadline for submission of essay to be announced on the homepage of the MIND programme and MRA programme
- Re-exam
The exam form for the reexam is the same as the ordinary exam. Se dates in the examplan on the homepage of the MIND programme and MRA programme
Criteria for exam assesment
To pass the exam, the participant must have written a comprehensive and structured report on a selected case in his/hers own words, which is based on relevant literature. This report should clearly demonstrate that the participant has gained:
Knowledge
- at basic level about risk management, design of experiments and PAT
Skills for
- applying basic risk analysis and design of experiments techniques into practical cases
identifying realistic process analytical tools for a given manufacturing environment
Competencies
- to work in a multidisciplinary risk management team
- to plan and implement basic design of experiments (DoE) approach
to suggest a QbD approach for constructing a design space.
Course information
- Language
- English
- Course code
- SMIMA1091U
- Credit
- 3 ECTS
- Level
- Part Time Master
- Duration
- 5 days
- Placement
- Autumn And Spring
- Schedule
- See MIND course page
- Course capacity
- 25 participants
Study board
- Study Board for the Professionel Master´s Degree Programmes at The Faculty og Health and Medical Science
Contracting department
- Department of Pharmacy
Contracting faculty
- Faculty of Health and Medical Sciences
Course Coordinators
- Jukka Rantanen (14-788379796f3c806f7c826f7c737c4e81837c723c79833c7279)
Lecturers
This course has elements of the framework developed by EUFEPS
QbD and PAT Sciences Network as published in "Strategic
framework for education and training in Quality by Design (QbD) and
process analytical technology (PAT)" Eur J Pharm Sci, 2016.
90:2-7.
doi: 10.1016/?j.ejps.2016.04.024
Selected industrial guest speakers will participate in teaching of
this course.